Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
174
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

257
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gastric-type Histology Independently Predicts Poor Survival in Surgically-treated Cervical Adenocarcinoma.

Anticancer research·2026
Same author

Effect of an Atelocollagen-Loaded Hyaluronic Acid-Based Porous Scaffold on Healing in a Rabbit Model of Chronic Rotator Cuff Tear.

Journal of shoulder and elbow surgery·2026
Same author

A 3D-Printed Scaffolded Hydrogel Microneedle Array Biosensor for Real-Time, Continuous Monitoring.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Advanced engineering of hydrogel platforms for cancer immunotherapy via distinct administration routes.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same author

Engineered 3D-Lattice Microneedle Array Patches for Enhanced Nanovaccine Delivery to Dendritic Cells in Cancer Immunotherapy.

ACS nano·2026
Same author

Assessing the temporal dynamics of airborne insect communities through DNA metabarcoding of aerial trap catches.

Scientific reports·2026
Same journal

ECG arrhythmia classification via wavelet-driven feature extraction and swarm-optimised gradient boosting.

Computers in biology and medicine·2026
Same journal

Electro-osmotic metachronal cilia transport of viscoelastic blood infused with penta-hybrid nanoparticles in an oviduct: Analytical and neural network modeling.

Computers in biology and medicine·2026
Same journal

sEEGnal: an automated EEG preprocessing pipeline evaluated against expert-driven preprocessing.

Computers in biology and medicine·2026
Same journal

Corrigendum to "Integrating experimental biology, computational methods, and artificial Intelligence in anticancer drug discovery: Bridging the translational Gap" [Comput. Biol. Med. 213 (2026) 111832].

Computers in biology and medicine·2026
Same journal

Organ dose optimization for a point-of-care forearm X-ray photon-counting CT.

Computers in biology and medicine·2026
Same journal

Physics-guided transformation of breathomic feature spaces into disease-specific representations for respiratory disease classification.

Computers in biology and medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 30, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K

Impartial feature selection using multi-agent reinforcement learning for adverse glycemic event prediction.

Seo-Hee Kim1, Dae-Yeon Kim2, Sung-Wan Chun2

  • 1Department of ICT Convergence, Soonchunhyang University, Asan, South Korea.

Computers in Biology and Medicine
|March 23, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces an attention model for predicting adverse glycemic events 30 minutes in advance in type 2 diabetes patients. The model uses Time2Vec and an impartial feature selection algorithm for improved glucose prediction accuracy.

Keywords:
Attention mechanismDeep learningFeature selectionMulti-agent learningReinforcement learning

More Related Videos

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

709
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Related Experiment Videos

Last Updated: Jun 30, 2025

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.5K
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

709
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K

Area of Science:

  • Biomedical Engineering
  • Artificial Intelligence in Medicine
  • Diabetes Management

Background:

  • Predicting glycemic events is crucial for managing type 2 diabetes.
  • Existing models may not fully capture the temporal dynamics of glucose levels, insulin, and meal intake.
  • Electronic medical records (EMRs) contain valuable features for predictive modeling.

Purpose of the Study:

  • To develop an attention model for predicting adverse glycemic events (hypoglycemia and hyperglycemia) 30 minutes in advance.
  • To incorporate temporal information of insulin administration and meal intake using Time2Vec.
  • To optimize feature selection from EMRs using an impartial algorithm.

Main Methods:

  • Developed an attention-based deep learning model for glucose prediction.
  • Utilized Time2Vec to encode temporal features like insulin and meal times.
  • Implemented an impartial feature selection algorithm based on agent contributions.
  • Evaluated the model on continuous glucose monitoring data from 102 type 2 diabetes patients.

Main Results:

  • Achieved high F1-scores for predicting glycemic states: 89.0% for normoglycemia, 60.6% for hypoglycemia, and 89.8% for hyperglycemia.
  • The model demonstrated effective encoding of temporal data for enhanced glucose prediction.
  • The feature selection algorithm improved overall model performance by optimizing EMR features.

Conclusions:

  • The proposed attention model with Time2Vec and advanced feature selection shows significant promise for real-time prediction of glycemic events in type 2 diabetes.
  • This approach can aid in proactive management and prevention of adverse glycemic outcomes.
  • Further validation in diverse clinical settings is warranted.